UDDEN death and embolism have long been feared as major hazards of quini-(dine in the treatment of atrial fibrillation. Isolated reports of untoward reactions began to appear shortly after the introduction of the drug by Frey in 1917. Viko, Marvin, and White' compiled the first sizable group of cases in 1923 dealing with this problem. In 484 patients, they reported 9 sudden deaths, 6 of which were presumed to he due to embolism. ' The over-all incidence of embolism, fatal and nonfatal, was 3.1 per cent; the incidence of sudden death was 1.8 per ceiit. IIi 1929, 1Parkin-,son and Campbell2 reported oti the basis of 554 cases a 4 per cent incidence of sudden death. This latter figure has been generally accepted as the standard risk. In contrast to the emphasis placed on embolism inl the earlier report, they noted that "hardly any of these *deaths were proved due to emboli, and in most of them necropsy showed no obvious structural disease to account for it [death] ". The most recent statistical data were presented by Askey3 in 1946. He reported on 839 cases, segregated into patients with and without congestive heart failure. Of 275 patients in failure, the incidence of death during treatment with quinidine was 4.0 per cent; in 564 cases not in failure, the incidence was 1.8 per (ent. Although no such separation was made in the preceding reports, congestive heart failure was believed to play an adverse role. M\ore recent authors have suggested that the hazards of embolism have been overemphasized, and that sudden death, though a possibility, is rare. 4 In the face of these confli(tin-ig data and National Heart Institute Trainee at Lenox Hill Hospital, N. X., 1953-1954. 757 impressions, it was believed that a review of more recent experiences was in order.
REVIEW OF REPORTED EXPERIENCES 1947-1954 Accordingly, 611 previously uncollected cases have been reviewed from 1947 to the end of 1954. The data given here are based on the experiences presented in 12 major reports, and are limited by their scope.5A'6 Patients were generally unselected as to the underlying cause of heart disease, its severity, the presence or absence of congestive heart failure, the duration of atrial fibrillation, or the association of other disease processes. Attention devoted to these details was so infrequent and involved so few cases that little of statistical significance about these variables was revealed.
In this group of 611 cases, 20 deaths occurred during therapy and were variously interpreted by the several authors. In the interests of uniformity all 20 deaths were arbitrarily regarded in this review as being caused by quinidine. The mean fatal incidence was 3.3 per cent. Clearly, in certain cases death could be attributed to other causes, making the adjusted death rate 2.1 per cent. This compares with Askey's3 over-all incidence of 2.5 per cent. This adjusted death rate of 2.1 per cent may be regarded as the maximal risk of sudden death from (uiniidine in this series. Table 1 reveals the wide range of total deaths in proportion to the total number of cases in various hands. The (rude death rate varied from 10 per cent in 1 series'5 to no deaths in 2 series." 9 MIc~lillan'0
QUINII)INE AS A CAUSE OF SUDDEN D)EATH
Bedard'5 Total THOUMSON mitral stenosis. In 10 cases where pathologic examination was permitted, embolism was implicated only once. This patient had rheumatic heart disease and died in pulmonary edema. Necropsy revealed multiple small pulmonary infarcts, fresh and old, and thrombosis of the superior mesenteric artery. In 2 cases without postmortem examination, undoubted cerebral embolism with hemiplegia occurred, followed by death in coma. The infrequency of pathologically verified embolism as a cause for sudden death is provocative. However, in none of the 10 cases necropsied was it specifically stated that examination of the brain was performed; no pathologically evident cause of death could be found, nor could embolism be implicated from evidence of intracardiac thrombi of peripheral emboli in 5 cases. III the remaining 5, the cause of death was determined at necropsy as indicated in table 1. On the other hand, where nonfatal embolism was observed, the brain was the most frequent site, manifested by signs of hemiplegia and aphasia. From the available data, in accord with the experience of Parkinson and Campbell,2 we are inclined to comment on how frequently no pathologically evident cause of sudden death could be found. However, valid conclusions regarding the cause of sudden death cannot be drawn from the limited necropsy data available; similarly, the inference of cerebral embolism does not seem warranted in view of these limitations.
Embolism was recognized clinically in 11 patients in a subgroup of 418 where the presence or absence of embolism was specifically noted (table 2 ). This is a clinical incidence of 2.3 per cent. Despite the notion that embolism most Since dosage is not sharply defined, the total dose and the time over which it is given reflect, among other things, the prevailing local conceptions of the drug's mode of action and toxicity and the evaluation of the clinical situation. But, most important of all appears to be the care exercised in the control of dosage, which amounts to the frequency with which observations of one or another type are made on the patient while he is receivinsg large doses of the drug. 2. In 10 fatalities studied at iiecropsy, embolism was implicated only once. In the majority, no pathologically evident cause of death could be found. Nearly half of the total deaths occurred in patients w'ith irheumatic heart disease and mitral stenosis. 3 . Prior embolism appears to carry a niegligible risk of repetition during quinidine treatment.
4. Where no arbitrary dosage limit is set, the mortality appears greater.
. Severe organic heart disease, conigestive heart failure, and associated grave illnesses increase the possibility of a fatal reaction. 6 . Unappreciated toxic effects of the drug, especially on the central niervous system, appear to play a role in the production of sudden death ("quinidine shock"). It is suggested that these effects might be avoided by a more judicious selection of patients for therapy and meticulous supervision of all patienits receiving large doses. These should be gathered after the flowering stem has shot up, and about the time that the blossoms are coming forth.
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The leaf-stalk and mid-rib of the leaves should be rejected, and the remaining part should be dried, either in the sun-shine, or on a tin pan or pewter dish before a fire.
If well dried, they readily rub down to a beautiful green powder, which weighs something less than one-fifth of the original weight of the leaves. Care must be taken that the leaves be not scorched in drying, and they should not be dried more than what is requisite to allow of their being readily reduced to powder.
I give to adults, from one to three grains of this powder twhice a day. In the reduced state in which physicians generally find dropsical patients, four grains a day are sufficient. I sometimes give the powder alone; sometimes unite it with aromatics, and sometimes form it into pills with a sufficient quantity of soap or gum ammoniac.-WILLIAM WITHERING. An Account of the Foxglove, and Some of Its Medical Uses. Birmingham, 1785.
